Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Leukocyte Biology

• Publication date

  2005-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1189/jlb.0604373PMID 15582984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.

  2005cited by this paper
• ZAP-70 expression and prognosis in chronic lymphocytic leukaemia.

  2004cited by this paper
• Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells

  2003cited by this paper
• Modulation of malignant B cell activation and apoptosis by bcl‐2 antisense ODN and immunostimulatory CpG ODN

  2002cited by this paper
• Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia

  2002cited by this paper
• Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides1

  2002cited by this paper
• Maintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells

  2002cited by this paper
• Toll-like receptors and their ligands.

  2002cited by this paper
• Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors.

  2002cited by this paper
• Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia.

  2002cited by this paper
• Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.

  2001cited by this paper
• CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens

  2001cited by this paper
• Effect of Immunostimulatory CpG-Oligonucleotides in Chronic Lymphocytic Leukemia B Cells

  2001cited by this paper
• Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.

  2000cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.

  2000cited by this paper
• Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.

  1998cited by this paper
• CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules

  1997cited by this paper
• Specific suppression of human tumor necrosis factor-alpha synthesis by antisense oligodeoxynucleotides.

  1996cited by this paper
• Specific Suppression of Human Tumor Necrosis Factor-α Synthesis by Antisense Oligodeoxynucleotides

  1996cited by this paper
• Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.

  1995cited by this paper
• CpG motifs in bacterial DNA trigger direct B-cell activation

  1995cited by this paper

• Revitalizing antitumor immunity: Leveraging nucleic acid sensors as therapeutic targets.

  2024cites this paper
• Biological effects of IL-21 on immune cells and its potential for cancer treatment.

  2023cites this paper
• In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia

  2023cites this paper
• Ex vivo culture of malignant primary B cells

  2022cites this paper
• TLR9 expression in Chronic Lymphocytic Leukemia identifies a pro-migratory subpopulation and novel therapeutic target.

  2021cites this paper
• Nucleic Acid Sensors as Therapeutic Targets for Human Disease.

  2020cites this paper
• Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases.

  2020cites this paper
• Nutrition, Immunity and Viral Infections

  2020cites this paper
• Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role

  2020cites this paper
• Cooperation of Oligodeoxynucleotides and Synthetic Molecules as Enhanced Immune Modulators

  2019cites this paper
• Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion

  2018cites this paper
• The regulatory capacity of B cells directs the aggressiveness of CLL

  2018cites this paper
• Interleukin 21 – its potential role in the therapy of B-cell lymphomas

  2017cites this paper
• Lack of Associations between TLR9 and MYD88 Gene Polymorphisms and Risk of Chronic Lymphocytic Leukemia

  2017cites this paper
• Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword.

  2017cites this paper
• Rôle de TLR7 dans la progression tumorale dans le cancer du poumon

  2017cites this paper
• Toll-like receptors targeting technology for the treatment of lymphoma

  2016influential citation
• NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.

  2016cites this paper
• Changes in expression of genes involved in antitumor immunity in mice vaccinated with tumor vaccine composed of irradiated syngeneic tumor cells and CpG oligodeoxynucleotides.

  2016cites this paper
• Myeloid cell leukaemia 1 has a vital role in retinoic acid‐mediated protection of Toll‐like receptor 9‐stimulated B cells from spontaneous and DNA damage‐induced apoptosis

  2016cites this paper
• Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies.

  2016cites this paper
• Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.

  2016cites this paper
• Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics

  2015cites this paper
• Patients with chronic lymphocytic leukaemia (CLL) differ in the pattern of CTLA-4 expression on CLL cells: the possible implications for immunotherapy with CTLA-4 blocking antibody

  2015cites this paper
• TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells

  2015cites this paper
• Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease

  2015cites this paper
• CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway

  2015cites this paper
• This information is current as Lymphocytic Leukemia B Cells Vitro Clonal Expansion of Chronic TLR-9 and IL-15 Synergy Promotes the In

  2015cites this paper
• Heterogeneous Functional Effects of Concomitant B Cell Receptor and TLR Stimulation in Chronic Lymphocytic Leukemia with Mutated versus Unmutated Ig Genes

  2014cites this paper
• B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.

  2014cites this paper
• Stereotyped B-cell receptors in chronic lymphocytic leukemia

  2014cites this paper
• Toll‐Like Receptors: Role in Inflammation and Cancer

  2014cites this paper
• Toll-like receptors in lymphoid malignancies: double-edged sword.

  2014cites this paper
• Toll-like receptor agonists induce apoptosis in mouse B-cell lymphoma cells by altering NF-κB activation

  2013cites this paper
• TLR9 signaling defines distinct prognostic subsets in CLL.

  2013cites this paper
• Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia.

  2013cites this paper
• Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine

  2013cites this paper
• The role of toll-like receptor 9 on B-cell activating factor expression and function in normal human B-cells

  2013cites this paper
• B cell receptor and antigens in CLL.

  2013cites this paper
• CpG ODN, Toll like receptor (TLR)-9 agonist, inhibits metastatic colon adenocarcinoma in a murine hepatic tumor model.

  2012cites this paper
• Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation

  2012cites this paper
• Mouse Models of Chronic Lymphocytic Leukemia

  2012cites this paper
• B Cell Growth, Differentiation and Malignancies

  2012cites this paper
• The microenvironment and treatment resistance in chronic lymphocytic leukemia

  2012cites this paper
• The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes

  2012cites this paper
• Los receptores tipo Toll en el desarrollo y función del sistema hematopoyético

  2012cites this paper
• Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy

  2012cites this paper
• Human B cells differentiate into granzyme B‐secreting cytotoxic B lymphocytes upon incomplete T‐cell help

  2012cites this paper
• Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

  2012cites this paper
• [Toll-like receptors in development and function of the hematopoietic system].

  2012cites this paper
• Stimulating natural killer cells to protect against cancer: recent developments

  2011cites this paper
• The role of toll-like receptor mediated signalling in the pathogenesis of multiple myeloma.

  2011cites this paper
• In vivo anti- and pro-tumour activities of the TLR2 ligand FSL-1.

  2011cites this paper
• The role of IL-21 in hematological malignancies.

  2011cites this paper
• The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

  2011cites this paper
• CpG Oligodeoxynucleotide 1826 Enhances the Lewis Lung Cancer Response to Radiotherapy in Murine Tumor

  2011cites this paper
• Interferon regulatory factors 1 and 4 in T cell mediated immune modulation

  2011cites this paper
• Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses

  2011cites this paper
• Toll‐like receptors on B‐CLL cells: expression and functional consequences of their stimulation

  2010influential citation
• Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.

  2010cites this paper
• The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia.

  2010cites this paper
• CD5+ B cells from individuals with systemic lupus erythematosus express granzyme B

  2010cites this paper
• Induction of targeted cell migration by cutaneous administration of a DNA vector encoding a biologically active chemokine CCL21.

  2010cites this paper
• Roles for TRAIL in the immune response to influenza virus infection

  2010cites this paper
• Development of a Murine model to dissect the CpG-oligonucleotide-enhancement of the killing of human B Cells by rituximab.

  2010cites this paper
• Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin‐2 stimulation: A Belgian multicentric study

  2009influential citation
• A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action

  2009influential citation
• Recognizing Viral Antigens in the Context of Human B Cells Secrete Granzyme B When

  2009cites this paper
• Autophagy links pattern recognition receptors to tumor cell apoptosis.

  2009cites this paper
• Human B Cells Secrete Granzyme B When Recognizing Viral Antigens in the Context of the Acute Phase Cytokine IL-211

  2009cites this paper
• CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.

  2009cites this paper
• The role of Toll-like receptors in chronic B cell malignancies

  2009cites this paper
• Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

  2009cites this paper
• Therapeutic applications of nucleic acids as ligands for Toll-like receptors.

  2009cites this paper
• Toll-like receptors and their role in hematologic malignancies.

  2009cites this paper
• Expression and function of toll like receptors in chronic lymphocytic leukaemia cells

  2009cites this paper
• Tumor-associated macrophages in the prospect of development of targeted anticancer

  2009cites this paper
• Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism.

  2008cites this paper
• Expression et fonctionnalité des Toll-Like récepteurs par les cellules de leucémie lymphoïde chronique B

  2008cites this paper
• Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

  2008cites this paper
• Combined treatment of CpG‐oligodeoxynucleotide with Nutlin‐3 induces strong immune stimulation coupled to cytotoxicity in B‐chronic lymphocytic leukemic (B‐CLL) cells

  2008cites this paper
• IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.

  2008cites this paper
• Toll-like receptors: lessons to learn from normal and malignant human B cells.

  2008cites this paper
• Toll-like receptors and their role in carcinogenesis and anti-tumor treatment

  2008cites this paper
• Toll-like receptors and immune regulation: implications for cancer therapy

  2008cites this paper
• Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-a-dependent mechanism

  2008cites this paper
• Biochemical and functional study of the immunomodulatory capacity of the soluble form of human Toll-like receptor 2

  2008cites this paper
• Clinical Development of Oligodeoxynucleotide TLR9 Agonists

  2008cites this paper
• Composés inhibiteurs de la croissance tumorale et leurs procédés d'utilisation

  2008cites this paper
• Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia

  2007cites this paper
• The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility

  2007cites this paper
• Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1

  2007cites this paper
• Reply to ‘Jahrsdorfer et al.’

  2007cites this paper
• Development of TLR9 agonists for cancer therapy.

  2007cites this paper
• Doctorate Program in Molecular Oncology and Endocrinology Doctorate School in Molecular Medicine

  2007cites this paper
• Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists

  2007cites this paper
• The Effects of Antigen Valency and CpG ODN on B Cells

  2007influential citation
• Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma

  2007cites this paper
• The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease

  2007cites this paper
• Phase I Trial ofToll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non^Hodgkin’s Lymphoma

  2007cites this paper